Drug Class
antineoplastic agents

Available Guidelines

  1. CPIC Guideline for capecitabine and DPYD
  2. CPIC Guideline for fluorouracil and DPYD
  3. CPIC Guideline for mercaptopurine and TPMT
  4. CPIC Guideline for thioguanine and TPMT
  5. PRO Guideline for irinotecan and UGT1A1
  6. DPWG Guideline for capecitabine and DPYD
  7. DPWG Guideline for fluorouracil and DPYD
  8. DPWG Guideline for irinotecan and UGT1A1
  9. DPWG Guideline for mercaptopurine and TPMT
  10. DPWG Guideline for thioguanine and TPMT

last updated 08/06/2014

1. CPIC Guideline for capecitabine and DPYD

Summary

The CPIC Dosing Guidelines for fluoropyrimidines (i.e. 5-fluorouracil, capecitabine or tegafur) recommends an alternative drug for patients who are homozygous for DPYD non-functional variants - *2A (rs3918290), *13 (rs55886062), and rs67376798 A (on the positive chromosomal strand) - as these patients are typically DPD deficient. Consider a 50% reduction in starting dose for heterozygous patients (intermediate activity).

There's more of this guideline. Read more.


last updated 07/30/2014

2. CPIC Guideline for fluorouracil and DPYD

Summary

The CPIC Dosing Guidelines for fluoropyrimidines (i.e. 5-fluorouracil, capecitabine or tegafur) recommends an alternative drug for patients who are homozygous for DPYD non-functional variants - *2A (rs3918290), *13 (rs55886062), and rs67376798 A (on the positive chromosomal strand) - as these patients are typically DPD deficient. Consider a 50% reduction in starting dose for heterozygous patients (intermediate activity).

There's more of this guideline. Read more.


last updated 05/10/2016

3. CPIC Guideline for mercaptopurine and TPMT

Summary

Start with reduced doses of mercaptopurine for patients with one nonfunctional TPMT allele, or drastically reduced doses for patients with malignancy and two nonfunctional alleles; adjust dose based on degree of myelosuppression and disease-specific guidelines. Consider alternative nonthiopurine immunosuppressant therapy for patients with nonmalignant conditions and two nonfunctional alleles.

There's more of this guideline. Read more.


last updated 05/10/2016

4. CPIC Guideline for thioguanine and TPMT

Summary

Start with reduced doses of thioguanine for patients with one nonfunctional TPMT allele, or drastically reduced doses for patients with malignancy and two nonfunctional alleles; adjust dose based on degree of myelosuppression and disease-specific guidelines. Consider alternative nonthiopurine immunosuppressant therapy for patients with nonmalignant conditions and two nonfunctional alleles.

There's more of this guideline. Read more.


last updated 06/03/2015

5. PRO Guideline for irinotecan and UGT1A1

Summary

A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of UGT1A1*28 genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the UGT1A1*28/*28 genotype, and that high-dose irinotecan (>=240 mg/m2) only be prescribed to patients with the UGT1A1*1/*1 genotype.

There's more of this guideline. Read more.


last updated 02/07/2014

6. DPWG Guideline for capecitabine and DPYD

Summary

Select an alternate drug to capecitabine for DPYD poor metabolizer patients, and reduce capecitabine dose (by 50%) or select an alternate drug for DPYD intermediate metabolizers.

There's more of this guideline. Read more.


last updated 02/07/2014

7. DPWG Guideline for fluorouracil and DPYD

Summary

An alternative drug rather than fluorouracil is recommended for DPYD poor metabolizer patients, and a reduced dose (by 50%) of fluorouracil or use of an alternative drug is recommended for intermediate metabolizer patients.

There's more of this guideline. Read more.






Annotated Labels

  1. FDA Label for afatinib and EGFR
  2. FDA Label for afutuzumab and MS4A1
  3. FDA Label for alemtuzumab
  4. FDA Label for arsenic trioxide and PML,RARA
  5. FDA Label for asparaginase
  6. FDA Label for bevacizumab
  7. FDA Label for bleomycin
  8. FDA Label for bortezomib
  9. FDA Label for bosutinib and ABL1,BCR
  10. FDA Label for brentuximab vedotin and TNFRSF8
  11. FDA Label for busulfan and ABL1,BCR
  12. FDA Label for capecitabine and DPYD
  13. FDA Label for carboplatin
  14. FDA Label for carmustine
  15. FDA Label for celecoxib and CYP2C9
  16. FDA Label for ceritinib and ALK
  17. FDA Label for cetuximab and EGFR,KRAS
  18. FDA Label for chlorambucil
  19. FDA Label for cisplatin and TPMT
  20. FDA Label for crizotinib and ALK
  21. FDA Label for cyclophosphamide
  22. FDA Label for cytarabine
  23. FDA Label for dabrafenib and BRAF
  24. FDA Label for dabrafenib and G6PD
  25. FDA Label for dacarbazine
  26. FDA Label for dasatinib and ABL1,BCR
  27. FDA Label for daunorubicin
  28. FDA Label for denileukin diftitox and IL2RA
  29. FDA Label for docetaxel
  30. FDA Label for doxorubicin
  31. FDA Label for epirubicin
  32. FDA Label for erlotinib and EGFR
  33. FDA Label for estramustine
  34. FDA Label for etoposide
  35. FDA Label for fludarabine
  36. FDA Label for fluorouracil and DPYD
  37. FDA Label for gefitinib and EGFR
  38. FDA Label for gemcitabine
  39. FDA Label for homoharringtonine and ABL1,BCR
  40. FDA Label for hydroxyurea
  41. FDA Label for ibrutinib
  42. FDA Label for idarubicin
  43. FDA Label for ifosfamide
  44. FDA Label for imatinib and ABL1,BCR,KIT
  45. FDA Label for irinotecan and UGT1A1
  46. FDA Label for Ixabepilone
  47. FDA Label for melphalan
  48. FDA Label for mercaptopurine and TPMT
  49. FDA Label for methotrexate
  50. FDA Label for mitoxantrone
  51. FDA Label for ofatumumab and MS4A1
  52. FDA Label for oxaliplatin
  53. FDA Label for paclitaxel
  54. FDA Label for panitumumab and EGFR,KRAS
  55. FDA Label for pazopanib and UGT1A1
  56. FDA Label for pemetrexed
  57. FDA Label for pertuzumab and ERBB2
  58. FDA Label for ponatinib and ABL1,BCR
  59. FDA Label for procarbazine
  60. FDA Label for regorafenib and EGFR,KRAS,VEGFA
  61. FDA Label for rituximab and MS4A1
  62. FDA Label for sorafenib
  63. FDA Label for sunitinib
  64. FDA Label for temozolomide
  65. FDA Label for temsirolimus
  66. FDA Label for teniposide
  67. FDA Label for thioguanine and TPMT
  68. FDA Label for thiotepa
  69. FDA Label for topotecan
  70. FDA Label for trametinib and BRAF
  71. FDA Label for trastuzumab and ERBB2
  72. FDA Label for trastuzumab emtansine and ERBB2
  73. FDA Label for tretinoin and PML,RARA
  74. FDA Label for vemurafenib and BRAF
  75. FDA Label for vincristine
  76. FDA Label for vinorelbine
  77. EMA Label for afatinib and EGFR
  78. EMA Label for arsenic trioxide and PML,RARA
  79. EMA Label for axitinib and CYP2C19,UGT1A1
  80. EMA Label for bosutinib and ABL1,BCR
  81. EMA Label for brentuximab vedotin and TNFRSF8
  82. EMA Label for capecitabine and DPYD
  83. EMA Label for ceritinib and ALK
  84. EMA Label for cetuximab and EGFR,KRAS
  85. EMA Label for crizotinib and ALK
  86. EMA Label for dabrafenib and BRAF
  87. EMA Label for dasatinib and ABL1,BCR
  88. EMA Label for erlotinib and EGFR,UGT1A1
  89. EMA Label for gefitinib and CYP2D6,CYP3A4,EGFR
  90. EMA Label for ibrutinib
  91. EMA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRB
  92. EMA Label for mercaptopurine and TPMT
  93. EMA Label for ofatumumab and MS4A1
  94. EMA Label for panitumumab and KRAS
  95. EMA Label for pazopanib and UGT1A1
  96. EMA Label for pertuzumab and ERBB2
  97. EMA Label for ponatinib and ABL1,BCR
  98. EMA Label for regorafenib and KRAS,UGT1A1
  99. EMA Label for rituximab and MS4A1
  100. EMA Label for sunitinib and CYP3A4
  101. EMA Label for trametinib and BRAF
  102. EMA Label for trastuzumab and ERBB2
  103. EMA Label for trastuzumab emtansine and ERBB2
  104. EMA Label for vandetanib and RET
  105. EMA Label for vemurafenib and BRAF
  106. PMDA Label for arsenic trioxide and PML,RARA
  107. PMDA Label for capecitabine and DPYD
  108. PMDA Label for celecoxib and CYP2C9
  109. PMDA Label for cetuximab and EGFR,KRAS
  110. PMDA Label for crizotinib and ALK
  111. PMDA Label for dasatinib and ABL1,BCR
  112. PMDA Label for fluorouracil and DPYD
  113. PMDA Label for gefitinib and EGFR
  114. PMDA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRA
  115. PMDA Label for irinotecan and UGT1A1
  116. PMDA Label for panitumumab and KRAS
  117. PMDA Label for trastuzumab and ERBB2
  118. PMDA Label for tretinoin and PML,RARA
  119. HCSC Label for afatinib and EGFR
  120. HCSC Label for afutuzumab and MS4A1
  121. HCSC Label for arsenic trioxide and PML,RARA
  122. HCSC Label for bosutinib and ABL1,BCR
  123. HCSC Label for brentuximab vedotin and TNFRSF8
  124. HCSC Label for capecitabine and DPYD
  125. HCSC Label for celecoxib and CYP2C9
  126. HCSC Label for ceritinib and ALK
  127. HCSC Label for cetuximab and EGFR,KRAS
  128. HCSC Label for crizotinib and ALK
  129. HCSC Label for dabrafenib and BRAF
  130. HCSC Label for dasatinib and ABI1,BCR
  131. HCSC Label for erlotinib and EGFR
  132. HCSC Label for fluorouracil and DPYD
  133. HCSC Label for gefitinib and EGFR
  134. HCSC Label for ibrutinib
  135. HCSC Label for imatinib and ABI1,BCR,FIP1L1,KIT,PDGFRA,PDGFRB
  136. HCSC Label for irinotecan and UGT1A1
  137. HCSC Label for mercaptopurine and TPMT
  138. HCSC Label for panitumumab and EGFR,KRAS
  139. HCSC Label for pertuzumab and ERBB2
  140. HCSC Label for ponatinib and ABI1,BCR
  141. HCSC Label for thioguanine and TPMT
  142. HCSC Label for trametinib and BRAF
  143. HCSC Label for trastuzumab and ERBB2
  144. HCSC Label for trastuzumab emtansine and ERBB2
  145. HCSC Label for tretinoin and PML,RARA
  146. HCSC Label for vemurafenib and BRAF

last updated 12/16/2013

1. FDA Label for afatinib and EGFR

Genetic testing required

Summary

Afatinib (GILOTRIF) is indicated for patients with metastatic non-small cell lung cancer (NSCLC) who have tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.

There's more of this label. Read more.


last updated 07/14/2014

2. FDA Label for afutuzumab and MS4A1

Informative PGx

Summary

Afutuzumab (GAZYVA; obinutuzumab) is used in combination with chlorambucil in patients with chronic lymphocytic leukemia who are previously untreated. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.

There's more of this label. Read more.



last updated 10/25/2013

4. FDA Label for arsenic trioxide and PML,RARA

Genetic testing required

Summary

The FDA-approved drug label for arsenic trioxide (Trisenox) contains information regarding indication of the drug in patients whose acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. The label also states that some patients treated with arsenic trioxide have experienced symptoms similar to a syndrome called the retinoic-acid-Acute Promyelocytic Leukemia (RA-APL) or APL differentiation syndrome, which can be fatal, and high-dose steroids (dexamethasone 10 mg intravenously BID) should be immediately initiated at the first signs.

There's more of this label. Read more.






last updated 12/16/2013

9. FDA Label for bosutinib and ABL1,BCR

Genetic testing required

Summary

The FDA-approved drug label for bosutinib (BOSULIF) notes that it is intended for adults with chronic, accelerated or blast phase Philadelphia chromosome-positive chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.

There's more of this label. Read more.


last updated 10/25/2013

10. FDA Label for brentuximab vedotin and TNFRSF8

Informative PGx

Summary

Brentuximab vedotin (Adcetris) is an antibody-drug conjugate (ADC) directed at TNFRSF8 (CD30), and nonclinical data suggests its anti-cancer mechanism of action is by binding to CD30-expressing cells and then releasing a small molecule that disrupts microtubules.

There's more of this label. Read more.


last updated 10/25/2013

11. FDA Label for busulfan and ABL1,BCR

Actionable PGx

Summary

The busulfan FDA-approved drug label states it is less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome. Testing for the BCR-ABL1 gene fusion is not mentioned in the drug label.

There's more of this label. Read more.


last updated 10/25/2013

12. FDA Label for capecitabine and DPYD

Actionable PGx

Summary

The FDA-approved label for capecitabine (Xeloda) notes that patients who have low or absent dihydropyrimidine dehydrogenase (DPD) activity are at increased risk for severe or fatal adverse reactions. However, the label does not mention genetic testing or screening for DPD activity.

There's more of this label. Read more.




last updated 06/13/2016

15. FDA Label for celecoxib and CYP2C9

Actionable PGx

Summary

Celecoxib is metabolized primarily by CYP2C9. Patients who are known or suspected to be poor CYP2C9 metabolizers should be administered celecoxib with caution. Consider a dose reduction by 50% (or alternative management for juvenile rheumatoid arthritis (JRA)) in patients who are known or suspected to be CYP2C9 poor metabolizers.

There's more of this label. Read more.


last updated 02/27/2015

16. FDA Label for ceritinib and ALK

Genetic testing required

Summary

The FDA-approved drug label for ceritinib (ZYKADIA) states that it is indicated for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

There's more of this label. Read more.


last updated 10/25/2013

17. FDA Label for cetuximab and EGFR,KRAS

Genetic testing required

Summary

Cetuximab is used in alone or in combination therapy to treat advanced squamous cell carcinoma of the head and neck and to treat K-Ras mutation-negative, EGFR expressing metastatic colorectal cancer. In cases of colorectal cancer, the label states "Determine K-Ras mutation and EGFR-expression status using FDA-approved tests prior to initiating treatment."

There's more of this label. Read more.



last updated 08/26/2016

19. FDA Label for cisplatin and TPMT

Informative PGx

Summary

The FDA-approved drug label for cisplatin was changed (in 2015) to reflect the level of uncertainty about the relationship between TPMT and cisplatin-induced ototoxicity. The Pharmacogenomics section was removed, and text was modified in the Warnings, Precautions and Adverse Reactions sections.

There's more of this label. Read more.


last updated 10/25/2013

20. FDA Label for crizotinib and ALK

Genetic testing required

Summary

The drug label for crizotinib (XALKORI) states that detection of ALK-positive non-small cell lung cancer (NSCLC) using an FDA-approved test is necessary for selection of patients for treatment with the drug, as it is only indicated for use in these patients.

There's more of this label. Read more.




last updated 03/02/2016

23. FDA Label for dabrafenib and BRAF

Genetic testing required

Summary

The drug label for dabrafenib (TAFINLAR) states that it is indicated for use in patients with unresectable or metastatic melanoma with a BRAF V600E mutation, or in combination with trametinib for patients with the V600K mutation, as detected by an FDA-approved test; the drug is not indicated for treatment of patients with wild-type BRAF melanoma.

There's more of this label. Read more.


last updated 12/16/2013

24. FDA Label for dabrafenib and G6PD

Actionable PGx

Summary

The drug label for dabrafenib (TAFINLAR) states that it is indicated for use in patients with unresectable or metastatic melanoma with a BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have a risk for developing hemolytic anemia, and that these patients should be closely observed when taking dabrafenib.

There's more of this label. Read more.



last updated 10/25/2013

26. FDA Label for dasatinib and ABL1,BCR

Genetic testing required

Summary

The FDA-approved drug label for dasatinib (SPRYCEL) notes that it is intended for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (Ph+ ALL) and resistance or intolerance to prior therapy.

There's more of this label. Read more.



last updated 10/25/2013

28. FDA Label for denileukin diftitox and IL2RA

Genetic testing required

Summary

The FDA-approved drug label for denileukin diftitox (Ontak) notes that it is indicated for patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. Confirmation of malignant cells expressing CD25 is necessary prior to administration of the drug.

There's more of this label. Read more.





last updated 10/25/2013

32. FDA Label for erlotinib and EGFR

Genetic testing required

Summary

TARCEVA (erlotinib) is a kinase inhibitor indicated for First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.

There's more of this label. Read more.





last updated 10/25/2013

36. FDA Label for fluorouracil and DPYD

Actionable PGx

Summary

Fluorouracil is available in both a topical cream and as an injection. These two formulations have different indications. Both FDA-approved labels contain information about the potential for severe toxicity in patients with dipyrimidine dehydrogenase (DPD) deficiency. However, neither label mentions testing for genetic variants or activity of DPD.

There's more of this label. Read more.


last updated 08/04/2016

37. FDA Label for gefitinib and EGFR

Genetic testing required

Summary

The FDA-approved drug label for gefinitib states that it is indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. The label also notes the potential clinical importance of considering CYP2D6 phenotype, though CYP2D6 testing is not mentioned.

There's more of this label. Read more.



last updated 12/18/2013

39. FDA Label for homoharringtonine and ABL1,BCR

Informative PGx

Summary

The FDA-approved drug label for omacetaxine mepesuccinate (homoharringtonine; SYNRIBO) notes that it is intended for adults with chronic or accelerated phase chronic myeloid leukemia (CML). The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).

There's more of this label. Read more.



last updated 05/29/2015

41. FDA Label for ibrutinib

Genetic testing required

Summary

Ibrutinib (IMBRUVICA) is a kinase inhibitor indicated for patients with multiple different cancer types, including those with chronic lymphocytic leukemia with 17p deletion.

There's more of this label. Read more.




last updated 10/25/2013

44. FDA Label for imatinib and ABL1,BCR,KIT

Genetic testing required

Summary

The decision of whether to treat patients with imatinib is based on the presence of genetic biomarkers, including BCR-ABL (the Philadelphia chromosome), KIT, and PDGFR gene rearrangements.

There's more of this label. Read more.


last updated 06/13/2016

45. FDA Label for irinotecan and UGT1A1

Actionable PGx

Summary

Individuals who are homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) are at increased risk for neutropenia following initiation of CAMPTOSAR treatment. A reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele

There's more of this label. Read more.




last updated 06/22/2016

48. FDA Label for mercaptopurine and TPMT

Genetic testing recommended

Summary

TPMT genotyping or phenotyping can identify patients who are homozygous deficient, which predisposes them to mercaptopurine toxicity, or who have low/intermediate TPMT activity, which makes them more likely to experience mercaptopurine toxicity than people with normal TPMT activity.

There's more of this label. Read more.




last updated 12/18/2013

51. FDA Label for ofatumumab and MS4A1

Informative PGx

Summary

Ofatumumab (ARZERRA) is used to treat patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.

There's more of this label. Read more.




last updated 10/25/2013

54. FDA Label for panitumumab and EGFR,KRAS

Genetic testing required

Summary

The panitumumab drug label contains information about EGFR-expressing metastatic colorectal carcinoma with disease progression on or following certain chemotherapy regimens. Detection of EGFR protein expression is necessary for selection of patients appropriate for Vectibix therapy. The label was updated to include information about treatment of patients with KRAS mutations. Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Vectibix is not recommended for the treatment of colorectal cancer with these mutations.

There's more of this label. Read more.


last updated 02/15/2014

55. FDA Label for pazopanib and UGT1A1

Actionable PGx

Summary

The drug label for pazopanib (VOTRIENT) states that patients with the UGT1A1 (TA)7/(TA)7 genotype (UGT1A1*28/*28) have an increased incidence of hyperbilirubinemia when taking pazopanib, as compared to those with the (TA)6/(TA)7 or (TA)6/(TA)6 genotype.

There's more of this label. Read more.



last updated 10/25/2013

57. FDA Label for pertuzumab and ERBB2

Genetic testing required

Summary

Pertuzumab is a targeted antibody drug designed to bind to ERBB2. Detection of HER2 protein overexpression is necessary for selection of patients appropriate for PERJETA therapy because these are the only patients studied and for whom benefit has been shown.

There's more of this label. Read more.


last updated 12/19/2013

58. FDA Label for ponatinib and ABL1,BCR

Actionable PGx

Summary

The FDA-approved drug label for ponatinib (Iclusig) states that it is intended for adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, including those with the BCR-ABL T315I mutation. The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).

There's more of this label. Read more.



last updated 01/14/2014

60. FDA Label for regorafenib and EGFR,KRAS,VEGFA

Informative PGx

Summary

The FDA-approved drug label for regorafenib (Stivarga) states that it is intended for patients with metastatic colorectal cancer who were previously given fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if they were KRAS wild type, an anti-EGFR therapy. The label does not specifically mention any form of genetic testing. This drug-biomarker pair was previously in the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" but has subsequently been removed.

There's more of this label. Read more.


last updated 01/14/2014

61. FDA Label for rituximab and MS4A1

Informative PGx

Summary

Rituximab (Rituxan) is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis or granulomatosis polyangiitis and microscopic polyangiitis. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.

There's more of this label. Read more.







last updated 06/22/2016

67. FDA Label for thioguanine and TPMT

Actionable PGx

Summary

The drug label recommends substantial dosage reductions for individuals with an inherited deficiency of the enzyme thiopurine methyltransferase (TPMT) to avoid the development of life-threatening bone marrow suppression in these patients. Prescribers should be aware that some laboratories offer testing for TPMT deficiency.

There's more of this label. Read more.




last updated 01/15/2014

70. FDA Label for trametinib and BRAF

Genetic testing required

Summary

The drug label for trametinib (MEKINIST) states that it is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

There's more of this label. Read more.


last updated 10/25/2013

71. FDA Label for trastuzumab and ERBB2

Genetic testing required

Summary

Trastuzumab (Herceptin) is used for the treatment of HER2 overexpressing node positive or node negative breast cancer, metastatic breast cancer and metastatic gastric cancer. The FDA requires test results demonstrating HER2 protein overexpression prior to initiating therapy.

There's more of this label. Read more.


last updated 10/25/2013

72. FDA Label for trastuzumab emtansine and ERBB2

Genetic testing required

Summary

The FDA-approved label requires test results demonstrating HER2 protein overexpression prior to initiating therapy with trastuzumab emtansine using FDA-approved tests by laboratories with demonstrated proficiency.

There's more of this label. Read more.


last updated 10/25/2013

73. FDA Label for tretinoin and PML,RARA

Genetic testing required

Summary

Tretinoin is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.

There's more of this label. Read more.


last updated 10/25/2013

74. FDA Label for vemurafenib and BRAF

Genetic testing required

Summary

Vemurafenib is a kinase inhibitor used to treat patients with unresectable or metastatic melanoma ONLY in cases where the BRAF V600E mutation is found by an FDA-approved test. In vitro evidence points to BRAF wild-type cells proliferation with exposure to BRAF inhibitors. Therefore, testing is required.

There's more of this label. Read more.




last updated 05/02/2014

77. EMA Label for afatinib and EGFR

Genetic testing required

Summary

Afatinib (GIOTRIF) is indicated in adult patients with non-small cell lung cancer with activating EGFR mutations. The EMA European Public Assessment Report (EPAR) for afatinib (GIOTRIF) states that EGFR mutation status should be established before initiation of afatinib therapy using a well-validated and robust methodology.

There's more of this label. Read more.


last updated 10/25/2013

78. EMA Label for arsenic trioxide and PML,RARA

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) contains pharmacogenetic information regarding the indication of arsenic trioxide in patients with APL characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RAR-alpha gene.

There's more of this label. Read more.


last updated 09/12/2014

79. EMA Label for axitinib and CYP2C19,UGT1A1

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for axitinib contains pharmacogenetic information related to there being no clinically relevant effects of UGT1A1 genotype or CYP2C19 genotype on axitinib pharmacokinetics.

There's more of this label. Read more.


last updated 03/31/2014

80. EMA Label for bosutinib and ABL1,BCR

Genetic testing required

Summary

The EMA EPAR for bosutinib (Bosulif) contains information regarding the indication of the drug in adult patients with Philadelphia chromosome positive chronic myelogenous leukaemia. This is due to its mechanism of action - the drug inhibits the abnormal BCR-ABL kinase that promotes chronic myelogenous leukaemia.

There's more of this label. Read more.


last updated 10/25/2013

81. EMA Label for brentuximab vedotin and TNFRSF8

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) contains information regarding the indication of brentuximab vedotin in patients with CD30-expressing tumour cells due to the drug's mechanism of action.

There's more of this label. Read more.


last updated 10/25/2013

82. EMA Label for capecitabine and DPYD

Actionable PGx

Summary

The EMA European Public Assessment Report (EPAR) highlights information regarding the contraindication of capecitabine in patients with known DPD (DPYD) deficiency due to an increased likelihood of severe, life-threatening or fatal toxicity. However, the label does not provide information regarding testing for DPD deficiency.

There's more of this label. Read more.


last updated 09/17/2015

83. EMA Label for ceritinib and ALK

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for ceritinib (Zykadia) states that it is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

There's more of this label. Read more.


last updated 10/25/2013

84. EMA Label for cetuximab and EGFR,KRAS

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) highlights information regarding the contraindication of Cetuximab (Erbitux) in colorectal cancer patients with tumors with KRAS mutations or if tumor status is not known.

There's more of this label. Read more.


last updated 10/25/2013

85. EMA Label for crizotinib and ALK

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) requires testing of ALK prior to treatment with crizotinib, indicated for patients with ALK-positive advanced non-small cell lung cancer.

There's more of this label. Read more.


last updated 05/02/2014

86. EMA Label for dabrafenib and BRAF

Genetic testing required

Summary

Dabrafenib (Tafinlar) is indicated in adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation due to its mechanism of action as an inhibitor of RAF kinases. The EMA European Public Assessment Report (EPAR) states that testing for tumor BRAF V600 mutations is required as efficacy and safety of dabrafenib has not been established in patients with wildtype BRAF.

There's more of this label. Read more.


last updated 10/25/2013

87. EMA Label for dasatinib and ABL1,BCR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) highlights information regarding the indication of Dasatinib (Sprycel) in patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia or acute lymphoblastic leukaemia.

There's more of this label. Read more.


last updated 10/25/2013

88. EMA Label for erlotinib and EGFR,UGT1A1

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) requires testing tumours for EGFR mutations in patients with non-small cell lung cancer prior to treatment with erlotinib and recommends using a well-validated method of testing. The drug should be used with caution in patients with low expression of UGT1A1 or Gilbert's disease (caused by genetic variants in UGT1A1 gene), due to the inhibitory effects of erlotinib on glucuronidation by UGT1A1 (UGT1A1 genetic testing is not required).

There's more of this label. Read more.


last updated 10/25/2013

89. EMA Label for gefitinib and CYP2D6,CYP3A4,EGFR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) contains biomarker information regarding the indication of gefitinib (Iressa) in patients with tumors that have activating EGFR mutations, due to its mechanism of action.

There's more of this label. Read more.


last updated 09/17/2015

90. EMA Label for ibrutinib

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for ibrutinib (IMBRUVICA) states that is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL), including those with the 17p deletion.

There's more of this label. Read more.


last updated 10/25/2013

91. EMA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRB

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.

There's more of this label. Read more.


last updated 05/29/2014

92. EMA Label for mercaptopurine and TPMT

Actionable PGx

Summary

The EMA European Public Assessment Report (EPAR) for mercaptopurine (Xaluprine) contains information regarding its metabolism by TPMT, and that patients with reduced activity are at increased risk of severe toxicity and likely require a reduced dose. TPMT genotyping or phenotyping can be used to identify these patients, although this should not replace close monitoring of blood counts.

There's more of this label. Read more.


last updated 05/29/2014

93. EMA Label for ofatumumab and MS4A1

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for ofatumumab (Arzerra) contains information regarding its mechanism of action by targeting CD20 (expressed by the MS4A1 gene).

There's more of this label. Read more.


last updated 10/27/2013

94. EMA Label for panitumumab and KRAS

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for panitumumab (Vectibix) contains information regarding the requirement for testing of KRAS mutations before initiating treatment, as the drug is indicated for patients with wildtype KRAS.

There's more of this label. Read more.


last updated 06/05/2014

95. EMA Label for pazopanib and UGT1A1

Actionable PGx

Summary

The EMA European Public Assessment Report (EPAR) for pazopanib (Votrient) states that the drug may cause mild hyperbilirubinemia in patients with Gilbert's syndrome (associated with reduced UGT1A1 activity and in some cases is caused by an underlying UGT1A1*28 variant) because it is an inhibitor of UGT1A1. It also states that pazopanib may have a greater effect on irinotecan active metabolite exposure in patients with the UGT1A1*28 variant.

There's more of this label. Read more.


last updated 06/13/2014

96. EMA Label for pertuzumab and ERBB2

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for pertuzumab (Perjeta) states that testing by a specialized laboratory must be performed to establish HER2 (ERBB2)-positive tumor status due to the action of the drug.

There's more of this label. Read more.


last updated 06/13/2014

97. EMA Label for ponatinib and ABL1,BCR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for ponatinib (Iclusig) states that indications of the drug include patients with Philadelphia chromosome positive (BCR-ABL1 gene fusion) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or patients who have the BCR-ABL T315I mutation, due to its mechanism of action as an inhibitor of BCR-ABL and inhibitor of mutant forms of the ABL kinase.

There's more of this label. Read more.


last updated 06/26/2014

98. EMA Label for regorafenib and KRAS,UGT1A1

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for regorafenib (Stivarga) is indicated in adult patients with metastatic colorectal cancer who have been previously treated with or are not considered candidates for other available therapies, including patients with KRAS mutant tumors, though physicians are recommended to carefully evaluate benefits and risks when prescribing regorafenib in patients with KRAS mutant tumours. It potentially blocks targets multiple protein kinases. It is also an inhibitor of UGT1A1 and therefore hyperbilirubinemia may occur in patients with Gilbert's syndrome (can be caused by genetic variants in the UGT1A1 gene).

There's more of this label. Read more.


last updated 07/10/2014

99. EMA Label for rituximab and MS4A1

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for rituximab (MabThera) contains information regarding one of the indications of the drug in patients with CD20-positive diffuse large V cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy regimen. The drug targets CD20 (MS4A1) expressing B cells to induce cell lysis.

There's more of this label. Read more.


last updated 09/16/2014

100. EMA Label for sunitinib and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for sunitinib (SUTENT) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and that potent CYP3A4 inhibitors or inducers should be avoided as they may affect sunitinib plasma levels.

There's more of this label. Read more.


last updated 09/17/2015

101. EMA Label for trametinib and BRAF

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for trametinib (Mekinist) states that it is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected using a validated test.

There's more of this label. Read more.


last updated 12/05/2013

102. EMA Label for trastuzumab and ERBB2

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for trastuzumab (Herceptin) requires testing of tumours for HER2 overexpression or gene amplification prior to initiating therapy. Trastuzumab (Herceptin) targets human epidermal growth factor receptor 2 (HER2) to inhibit growth of HER2 overexpressing cancer cells.

There's more of this label. Read more.


last updated 07/10/2014

103. EMA Label for trastuzumab emtansine and ERBB2

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for trastuzumab emtansine (Kadcyla) contains information regarding indication of the drug in patients with HER2-positive (encoded by the ERBB2 gene) breast cancer due to its mechanism of action, and HER2 positive status should be tested for by a validated method.

There's more of this label. Read more.


last updated 08/06/2014

104. EMA Label for vandetanib and RET

Genetic testing recommended

Summary

The EMA European Public Assessment Report (EPAR) for vandetanib (Caprelsa) recommends testing for RET mutation status, as patients without RET mutations may have decreased benefit from vandetanib treatment.

There's more of this label. Read more.


last updated 12/05/2013

105. EMA Label for vemurafenib and BRAF

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for vemurafenib (Zelboraf) requires testing of tumours for the BRAF V600 mutation prior to initiating treatment.

There's more of this label. Read more.


last updated 01/26/2015

106. PMDA Label for arsenic trioxide and PML,RARA

Genetic testing required

Summary

Arsenic trioxide is indicated for treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). The PMDA package insert for arsenic trioxide states that patients with APL should be characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

There's more of this label. Read more.


last updated 01/26/2015

107. PMDA Label for capecitabine and DPYD

Actionable PGx

Summary

The PMDA package insert for capecitabine states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of capecitabine and other fluoropyrimidines.

There's more of this label. Read more.


last updated 08/18/2016

108. PMDA Label for celecoxib and CYP2C9

Informative PGx

Summary

The PMDA package insert for celecoxib notes that individuals with the CYP2C9 *1/*3 genotype have an increased median area under the concentration-time curve (AUC) as compared to those with the CYP2C9 *1/*1 (wild-type) genotype.

There's more of this label. Read more.


last updated 01/26/2015

109. PMDA Label for cetuximab and EGFR,KRAS

Genetic testing required

Summary

The PMDA package insert for cetuximab states that it is indicated for individuals with epidermal growth factor receptor (EGFR)-expressing colorectal cancer. It also notes that KRAS mutational status should be considered for selecting patients with EGFR-expressing colorectal cancer.

There's more of this label. Read more.


last updated 01/26/2015

110. PMDA Label for crizotinib and ALK

Genetic testing required

Summary

The PMDA package insert for crizotinib states that it is indicated for individuals with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC).

There's more of this label. Read more.


last updated 01/26/2015

111. PMDA Label for dasatinib and ABL1,BCR

Genetic testing required

Summary

The PMDA package insert for dasatinib states that it is indicated for individuals with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

There's more of this label. Read more.


last updated 01/26/2015

112. PMDA Label for fluorouracil and DPYD

Actionable PGx

Summary

The PMDA package insert for fluorouracil states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of fluorouracil and other fluoropyrimidines.

There's more of this label. Read more.


last updated 01/26/2015

113. PMDA Label for gefitinib and EGFR

Genetic testing required

Summary

The PMDA package insert for gefitinib states that it is indicated for patients with EGFR activating mutation positive non-small cell lung cancer (NSCLC), and that EGFR mutation testing should be performed prior to beginning gefitinib treatment.

There's more of this label. Read more.


last updated 01/26/2015

114. PMDA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRA

Genetic testing required

Summary

The PMDA package insert for imatinib contains pharmacogenetic information regarding the indication of the drug in patients with the Kit (CD117)-positive tumors, hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFR a rearrangement, or Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.

There's more of this label. Read more.


last updated 01/26/2015

115. PMDA Label for irinotecan and UGT1A1

Actionable PGx

Summary

The PMDA package insert for irinotecan states that individuals who are homozygous for the UGT1A1*6 or *28 alleles, or heterozygous with the *6/*28 genotype, are at an increased risk for severe adverse events, particularly neutropenia.

There's more of this label. Read more.


last updated 01/26/2015

116. PMDA Label for panitumumab and KRAS

Genetic testing required

Summary

The PMDA package insert for panitumumab states that it is indicated for patients with wild-type KRAS colorectal cancer, and that treatment benefit has not been shown in KRAS mutation-positive patients.

There's more of this label. Read more.


last updated 01/26/2015

117. PMDA Label for trastuzumab and ERBB2

Genetic testing required

Summary

The PMDA package insert for trastuzumab states that it is indicated for patients with HER2-overexpressing breast or gastric cancers.

There's more of this label. Read more.


last updated 01/26/2015

118. PMDA Label for tretinoin and PML,RARA

Informative PGx

Summary

Tretinoin is indicated for the treatment of acute promyelocytic leukemia (APL). The PMDA package insert for tretinoin notes that it acts on the PML-RARa fusion gene, allowing immature promyelocytes to differentiate into normal mature blood cells.

There's more of this label. Read more.


last updated 06/08/2015

119. HCSC Label for afatinib and EGFR

Genetic testing required

Summary

The product monograph for afatinib (GIOTRIF) states that it is indicated for the treatment of patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s), including exon 19 deletions and the exon 21 L858R point mutation. A validated test is required to identify EGFR mutation status.

There's more of this label. Read more.



last updated 06/08/2015

121. HCSC Label for arsenic trioxide and PML,RARA

Genetic testing required

Summary

The product monograph for arsenic trioxide (TRISENOX) states that is indicated for patients with acute promyelotic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic-acid-receptor alpha (PML-RARa) gene expression.

There's more of this label. Read more.


last updated 06/08/2015

122. HCSC Label for bosutinib and ABL1,BCR

Genetic testing required

Summary

The product monograph for bosutinib (BOSULIF) states that it is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.

There's more of this label. Read more.



last updated 08/24/2016

124. HCSC Label for capecitabine and DPYD

Actionable PGx

Summary

The product monograph for capecitabine states that it is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. However, genetic testing or screening for DPD deficiency is not mentioned.

There's more of this label. Read more.


last updated 06/08/2015

125. HCSC Label for celecoxib and CYP2C9

Actionable PGx

Summary

The product monograph for celecoxib (CELEBREX) notes that patients who are CYP2C9 poor metabolizers should be administered celecoxib with caution. It further states that the drug should be introduced at half the lowest recommended dose in these individuals, with a maximum recommended dose of 100 mg/day. However, the product monograph does not discuss CYP2C9 genotyping prior to treatment.

There's more of this label. Read more.


last updated 10/22/2015

126. HCSC Label for ceritinib and ALK

Genetic testing required

Summary

Ceritinib (ZYKADIA) is indicated as a monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer who have progressed on or were intolerant to crizotinib.

There's more of this label. Read more.


last updated 06/08/2015

127. HCSC Label for cetuximab and EGFR,KRAS

Genetic testing required

Summary

The product monograph for cetuximab (ERBITUX) states that it is indicated for treatment of EGFR-expressing K-ras wild-type metastatic colorectal carcinoma.

There's more of this label. Read more.


last updated 06/08/2015

128. HCSC Label for crizotinib and ALK

Genetic testing required

Summary

The product monograph for crizotinib (XALKORI) states that it is indicated for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.

There's more of this label. Read more.


last updated 06/08/2015

129. HCSC Label for dabrafenib and BRAF

Genetic testing required

Summary

The product monograph for dabrafenib (TAFINLAR) states that it is indicated for treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

There's more of this label. Read more.


last updated 06/08/2015

130. HCSC Label for dasatinib and ABI1,BCR

Genetic testing required

Summary

The product monograph for dasatinib (SPRYCEL) states that it is indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

There's more of this label. Read more.


last updated 06/08/2015

131. HCSC Label for erlotinib and EGFR

Genetic testing required

Summary

The product monograph for erlotinib (TARCEVA) states that it is indicated for patients with non-small cell lung cancer (NSCLC) who have a confirmed activating EGFR mutation.

There's more of this label. Read more.


last updated 06/08/2015

132. HCSC Label for fluorouracil and DPYD

Actionable PGx

Summary

The product monograph for fluorouracil states that it should be used with care in patients who have a dihydropyrimidine dehydrogenase (DYPD) deficiency, due to the risk for experiencing toxicity.

There's more of this label. Read more.


last updated 06/08/2015

133. HCSC Label for gefitinib and EGFR

Genetic testing required

Summary

The product monograph for gefitinib (IRESSA) states that it is indicated for patients with activating EGFR mutations, and should not be used in those with EGFR mutation negative tumors.

There's more of this label. Read more.


last updated 06/08/2015

134. HCSC Label for ibrutinib

Genetic testing required

Summary

The product monograph for ibrutinib (IMBRUVICA) states that it is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL), including those with the 17p deletion.

There's more of this label. Read more.


last updated 06/08/2015

135. HCSC Label for imatinib and ABI1,BCR,FIP1L1,KIT,PDGFRA,PDGFRB

Genetic testing required

Summary

The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.

There's more of this label. Read more.


last updated 06/08/2015

136. HCSC Label for irinotecan and UGT1A1

Actionable PGx

Summary

The product monograph for irinotecan (CAMPTOSAR) notes that a reduced irinotecan starting dose should be considered in individuals homozygous for the UGT1A1*28 (rs8175347) allele, due to the risk for hematologic toxicity.

There's more of this label. Read more.


last updated 06/08/2015

137. HCSC Label for mercaptopurine and TPMT

Actionable PGx

Summary

The product monograph for mercaptopurine (PURINETHOL) states that individuals who are TPMT deficient are at risk of developing life-threatening bone marrow suppression when receiving the drug, and that substantial dose reductions are usually required for these individuals.

There's more of this label. Read more.


last updated 06/08/2015

138. HCSC Label for panitumumab and EGFR,KRAS

Genetic testing required

Summary

The product monograph for panitumumab (VECTIBIX) states that it is indicated for patients with EGFR-expressing metastatic colorectal carcinoma (mCRC) with wild-type KRAS, and should not be used in patients with KRAS-mutant mCRC or for whom KRAS mutation status is unknown.

There's more of this label. Read more.


last updated 06/08/2015

139. HCSC Label for pertuzumab and ERBB2

Genetic testing required

Summary

The product monograph for pertuzumab (PERJETA) states that it is indicated in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer.

There's more of this label. Read more.


last updated 10/22/2015

140. HCSC Label for ponatinib and ABI1,BCR

Genetic testing required

Summary

Ponatinib (ICLUSIG) is indicated for adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including CML or Ph+ ALL that is T315I mutation positive. The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion). The T315I mutation is known to cause resistance to other BCR-ABL kinase inhibitors.

There's more of this label. Read more.


last updated 06/08/2015

141. HCSC Label for thioguanine and TPMT

Actionable PGx

Summary

The product monograph for thioguanine (LANVIS) notes that individuals with deficiency of the thiopurine methyltransferase (TPMT) enzyme may be at increased risk of developing myelosuppression when receiving the drug, and that testing for TPMT deficiency is available.

There's more of this label. Read more.


last updated 06/08/2015

142. HCSC Label for trametinib and BRAF

Genetic testing required

Summary

The product monograph for trametinib (MEKINIST) states that it is indicated for patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

There's more of this label. Read more.


last updated 06/08/2015

143. HCSC Label for trastuzumab and ERBB2

Genetic testing required

Summary

The product monograph for trastuzumab (HERCEPTIN) states that it is indicated for patients with early or metastatic breast cancer, or metastatic adenocarcinoma of the stomach or gastroesophageal junction, whose tumors are HER2 positive.

There's more of this label. Read more.


last updated 06/08/2015

144. HCSC Label for trastuzumab emtansine and ERBB2

Genetic testing required

Summary

The product monograph for trastuzumab emtansine (KADCYLA) states that it is indicated for patients with HER2-positive, metastatic breast cancer who received prior treatment with trastuzumab and a taxane, separately or in combination.

There's more of this label. Read more.


last updated 06/08/2015

145. HCSC Label for tretinoin and PML,RARA

Genetic testing required

Summary

Tretinoin (VESANOID) is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.

There's more of this label. Read more.


last updated 06/08/2015

146. HCSC Label for vemurafenib and BRAF

Genetic testing required

Summary

The product monograph for vemurafenib (ZELBORAF) states that it is indicated for the treatment of patients with BRAF V600 mutation-positive melanoma, and that it should not be used in patients with BRAF wild-type melanoma.

There's more of this label. Read more.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for antineoplastic agents

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2B6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1xN N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *5 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *7 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *9 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *14 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *10x2 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *20 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *21 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *35 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *36 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *41 N/A N/A N/A
No VIP available No VIP available VA UGT2B15 *1 N/A N/A N/A
No VIP available No VIP available VA UGT2B15 *2 N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 extensive metabolizers N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizers N/A N/A N/A
No VIP available CA No Variant Annotations available
rs1042522 NC_000017.10:g.7579472G=, NC_000017.10:g.7579472G>C, NC_000017.10:g.7579472G>T, NC_000017.11:g.7676154G=, NC_000017.11:g.7676154G>C, NC_000017.11:g.7676154G>T, NG_017013.2:g.16397C=, NG_017013.2:g.16397C>A, NG_017013.2:g.16397C>G, NM_000546.5:c.215C=, NM_000546.5:c.215C>A, NM_000546.5:c.215C>G, NM_001126112.2:c.215C=, NM_001126112.2:c.215C>A, NM_001126112.2:c.215C>G, NM_001126113.2:c.215C=, NM_001126113.2:c.215C>A, NM_001126113.2:c.215C>G, NM_001126114.2:c.215C=, NM_001126114.2:c.215C>A, NM_001126114.2:c.215C>G, NM_001126115.1:c.-939C=, NM_001126115.1:c.-939C>A, NM_001126115.1:c.-939C>G, NM_001126116.1:c.-939C=, NM_001126116.1:c.-939C>A, NM_001126116.1:c.-939C>G, NM_001126117.1:c.-939C=, NM_001126117.1:c.-939C>A, NM_001126117.1:c.-939C>G, NM_001126118.1:c.98C=, NM_001126118.1:c.98C>A, NM_001126118.1:c.98C>G, NM_001276695.1:c.98C=, NM_001276695.1:c.98C>A, NM_001276695.1:c.98C>G, NM_001276696.1:c.98C=, NM_001276696.1:c.98C>A, NM_001276696.1:c.98C>G, NM_001276697.1:c.-1020C=, NM_001276697.1:c.-1020C>A, NM_001276697.1:c.-1020C>G, NM_001276698.1:c.-1020C=, NM_001276698.1:c.-1020C>A, NM_001276698.1:c.-1020C>G, NM_001276699.1:c.-1020C=, NM_001276699.1:c.-1020C>A, NM_001276699.1:c.-1020C>G, NM_001276760.1:c.98C=, NM_001276760.1:c.98C>A, NM_001276760.1:c.98C>G, NM_001276761.1:c.98C=, NM_001276761.1:c.98C>A, NM_001276761.1:c.98C>G, NP_000537.3:p.Pro72=, NP_000537.3:p.Pro72Arg, NP_000537.3:p.Pro72His, NP_001119584.1:p.Pro72=, NP_001119584.1:p.Pro72Arg, NP_001119584.1:p.Pro72His, NP_001119585.1:p.Pro72=, NP_001119585.1:p.Pro72Arg, NP_001119585.1:p.Pro72His, NP_001119586.1:p.Pro72=, NP_001119586.1:p.Pro72Arg, NP_001119586.1:p.Pro72His, NP_001119590.1:p.Pro33=, NP_001119590.1:p.Pro33Arg, NP_001119590.1:p.Pro33His, NP_001263624.1:p.Pro33=, NP_001263624.1:p.Pro33Arg, NP_001263624.1:p.Pro33His, NP_001263625.1:p.Pro33=, NP_001263625.1:p.Pro33Arg, NP_001263625.1:p.Pro33His, NP_001263689.1:p.Pro33=, NP_001263689.1:p.Pro33Arg, NP_001263689.1:p.Pro33His, NP_001263690.1:p.Pro33=, NP_001263690.1:p.Pro33Arg, NP_001263690.1:p.Pro33His, XM_005256778.1:c.176-21C=, XM_005256778.1:c.176-21C>A, XM_005256778.1:c.176-21C>G, XR_243565.1:n.354C=, XR_243565.1:n.354C>A, XR_243565.1:n.354C>G, XR_243566.1:n.354C=, XR_243566.1:n.354C>A, XR_243566.1:n.354C>G, rs17844988, rs17857747, rs17882155, rs2229076, rs3174747, rs4134781, rs60388830
G > C
SNP
P72R
No VIP available No Clinical Annotations available VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1059829 NC_000005.10:g.151662468G>A, NC_000005.9:g.151042029G>A, NG_042174.1:g.29587C>T, NM_001309443.1:c.*1103C>T, NM_001309444.1:c.*987C>T, NM_003118.3:c.*1103C>T, rs17718221, rs1804457, rs3210713, rs3822701, rs59831535
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available CA VA
rs17091162 NC_000014.8:g.95089232C>A, NC_000014.9:g.94622895C>A, NG_012879.1:g.15519C>A, NM_001085.4:c.1068+404C>A, XM_005267307.1:c.1143+404C>A, XM_005267308.1:c.1068+404C>A, XR_245663.1:n.899+404C>A, rs60560586
C > A
SNP
No VIP available CA VA
rs1760217 NC_000001.10:g.97602994A>G, NC_000001.11:g.97137438A>G, NG_008807.2:g.788622T>C, NM_000110.3:c.2623-38806T>C, NR_046590.1:n.64+41452A>G, XM_005270561.1:c.2512-38806T>C, XM_005270562.1:c.2407-38806T>C, XM_005270562.3:c.2407-38806T>C, rs17472184, rs58395723
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1801133 NC_000001.10:g.11856378G>A, NC_000001.11:g.11796321G>A, NG_013351.1:g.14783C>T, NM_005957.4:c.665C>T, NP_005948.3:p.Ala222Val, XM_005263458.1:c.788C>T, XM_005263458.2:c.788C>T, XM_005263459.1:c.734C>T, XM_005263460.1:c.665C>T, XM_005263460.3:c.665C>T, XM_005263461.1:c.665C>T, XM_005263461.3:c.665C>T, XM_005263462.1:c.665C>T, XM_005263462.3:c.665C>T, XM_005263463.1:c.419C>T, XM_005263463.2:c.419C>T, XM_011541495.1:c.785C>T, XM_011541496.1:c.788C>T, XP_005263515.1:p.Ala263Val, XP_005263516.1:p.Ala245Val, XP_005263517.1:p.Ala222Val, XP_005263518.1:p.Ala222Val, XP_005263519.1:p.Ala222Val, XP_005263520.1:p.Ala140Val, XP_011539797.1:p.Ala262Val, XP_011539798.1:p.Ala263Val, rs386545618, rs4134713, rs59514310
G > A
SNP
A222V
No VIP available No Clinical Annotations available VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available No Clinical Annotations available VA
rs2231142 NC_000004.11:g.89052323G>T, NC_000004.12:g.88131171G>T, NG_032067.2:g.105152C>A, NM_001257386.1:c.421C>A, NM_004827.2:c.421C>A, NP_001244315.1:p.Gln141Lys, NP_004818.2:p.Gln141Lys, XM_005263354.1:c.421C>A, XM_005263354.2:c.421C>A, XM_005263355.1:c.421C>A, XM_005263355.2:c.421C>A, XM_005263356.1:c.421C>A, XM_005263356.2:c.421C>A, XM_011532420.1:c.421C>A, XP_005263411.1:p.Gln141Lys, XP_005263412.1:p.Gln141Lys, XP_005263413.1:p.Gln141Lys, XP_011530722.1:p.Gln141Lys, rs12721641, rs28365035, rs3736117, rs52809243, rs58973676
G > T
SNP
Q141K
No VIP available No Clinical Annotations available VA
rs2231164 NC_000004.11:g.89015857C>T, NC_000004.12:g.88094705C>T, NG_032067.2:g.141618G>A, NM_001257386.1:c.1728-46G>A, NM_004827.2:c.1738-46G>A, XM_005263354.1:c.1738-46G>A, XM_005263354.2:c.1738-46G>A, XM_005263355.1:c.1738-46G>A, XM_005263355.2:c.1738-46G>A, XM_005263356.1:c.1732-46G>A, XM_005263356.2:c.1732-46G>A, XM_011532420.1:c.1738-46G>A, rs3816742, rs386561805, rs59707155
C > A
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2274407 NC_000013.10:g.95859035C>A, NC_000013.11:g.95206781C>A, NM_001105515.2:c.912G>T, NM_001301829.1:c.912G>T, NM_001301830.1:c.687G>T, NM_005845.4:c.912G>T, NP_001098985.1:p.Lys304Asn, NP_001288758.1:p.Lys304Asn, NP_001288759.1:p.Lys229Asn, NP_005836.2:p.Lys304Asn, XM_005254025.1:c.783G>T, XM_005254025.2:c.783G>T, XM_005254026.1:c.912G>T, XM_005254027.1:c.687G>T, XM_005254028.1:c.687G>T, XM_006719914.1:c.912G>T, XM_011521047.1:c.363G>T, XP_005254082.1:p.Lys261Asn, XP_005254083.1:p.Lys304Asn, XP_005254084.1:p.Lys229Asn, XP_005254085.1:p.Lys229Asn, XP_006719977.1:p.Lys304Asn, XP_011519349.1:p.Lys121Asn, rs117944872, rs52813831, rs58221897
C > A
SNP
K304N
No VIP available No Clinical Annotations available VA
rs2740574 NC_000007.13:g.99382096C>T, NC_000007.14:g.99784473C>T, NG_008421.1:g.4713G>A, NM_001202855.2:c.-392G>A, NM_017460.5:c.-392G>A, XM_011515841.1:c.-392G>A, XM_011515842.1:c.-392G>A, rs3176920, rs36231114, rs59393892
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4502225 NC_000016.10:g.78390934T>C, NC_000016.9:g.78424831T>C, NG_011698.1:g.296281T>C, NM_001291997.1:c.266+3986T>C, NM_016373.3:c.605+3986T>C, XM_005255980.1:c.409+275780T>C, XM_005255981.1:c.266+3986T>C, XM_005255982.1:c.516+226645T>C, XM_006721195.2:c.605+3986T>C, XM_011523100.1:c.605+3986T>C, XM_011523101.1:c.605+3986T>C, XM_011523102.1:c.605+3986T>C, XM_011523103.1:c.605+3986T>C, XM_011523104.1:c.605+3986T>C, XR_243411.1:n.730+3986T>C, rs60064696
T > C
SNP
No VIP available CA VA
rs6500843 NC_000016.10:g.6820854A>G, NC_000016.9:g.6870855A>G, NG_011881.1:g.806724A>G, NM_001142333.1:c.-16+166204A>G, NM_001142334.1:c.-16+46841A>G, NM_001308117.1:c.114+166204A>G, NM_018723.3:c.-16+166204A>G, XM_005255378.1:c.462+166204A>G, XM_005255379.1:c.114+166204A>G, XM_005255379.2:c.114+166204A>G, XM_005255380.1:c.93+166204A>G, XM_005255380.2:c.93+166204A>G, XM_005255384.1:c.-16+166204A>G, XM_005255384.2:c.-16+166204A>G, XM_005255385.1:c.-16+166204A>G, XM_005255385.3:c.-16+166204A>G, XM_005255389.1:c.114+166204A>G, XM_005255389.2:c.114+166204A>G, XM_005255390.1:c.-16+166204A>G, XM_005255390.2:c.-16+166204A>G, XM_005255391.1:c.-16+166204A>G, XM_005255391.2:c.-16+166204A>G, XM_005255392.1:c.-16+166204A>G, XM_005255395.1:c.93+166204A>G, XM_011522544.1:c.462+166204A>G, rs60379811
A > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
Brand Mixture Names

PharmGKB Accession Id

PA452621

Other Vocabularies

Drugs And Small Molecules

The following have been classified under this therapeutic category:

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to antineoplastic agents: 55

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast cancer research and treatment. 2015. Ellingson Marissa S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Pui Ching-Hon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget. 2015. Fagerholm Rainer, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics. 2015. Sosa-Macias Martha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome. PloS one. 2015. Shamai Sivan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Significant association of combination of OCT4, NANOG, and SOX2 gene polymorphisms in susceptibility and response to treatment in North Indian breast cancer patients. Cancer chemotherapy and pharmacology. 2014. Tulsyan Sonam, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.]. 2014. Martins D M F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer chemotherapy and pharmacology. 2014. Mwinyi Jessica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of pro-arrhythmic adverse drug reactions. British journal of clinical pharmacology. 2014. Petropoulou Evmorfia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Conventional dosing of anticancer agents: precisely wrong or just inaccurate?. Clinical pharmacology and therapeutics. 2014. Bins S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Medical oncology (Northwood, London, England). 2014. Zhao Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic oncology. 2013. Johnatty Sharon E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast cancer research and treatment. 2013. Dezentjé V O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics. 2013. Margolin Sara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients. Cancer chemotherapy and pharmacology. 2013. Trojan Andreas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmacogenomics and personalized medicine. 2013. Chamnanphon Montri, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer chemotherapy and pharmacology. 2012. Damodaran Solai Elango, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence. The pharmacogenomics journal. 2012. Winder T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast cancer research and treatment. 2012. Park In Hae, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics. 2012. Khrunin Andrey, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pacific journal of cancer prevention : APJCP. 2012. Sukasem Chonlaphat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. Journal of Korean medical science. 2011. Park Hyung Seok, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics. 2011. van Schaik Ron H N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas. 2011. Zeng Hongmei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. Journal of the National Cancer Institute. 2011. Lash Timothy L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast cancer research and treatment. 2011. Thompson Alastair M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer epidemiology. 2010. Henríquez-Hernández Luis Alberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatric hematology and oncology. 2010. Horinouchi Masanori, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenetics and genomics. 2010. Kiyotani Kazuma, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. The pharmacogenomics journal. 2010. Khrunin A V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast cancer research and treatment. 2010. Ramón y Cajal T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). British journal of pharmacology. 2010. Zhou Fanfan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009. Ansari Marc, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer chemotherapy and pharmacology. 2009. Kim Jong Gwang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009. Okishiro Masatsugu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009. Chang H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. Journal of experimental therapeutics & oncology. 2009. Ishikawa Toshihisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. Journal of cancer research and clinical oncology. 2008. Huang Zhao-Hui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008. Newman William G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008. Xu Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics. 2008. Ward Michael B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007. Moyer Ann M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. British journal of haematology. 2007. Bolufer Pascual, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Yang Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism discovery in 51 chemotherapy pathway genes. Human molecular genetics. 2005. Freimuth Robert R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer research. 2005. Huang Ying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast cancer research and treatment. 2005. Nowell Susan A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast cancer research : BCR. 2005. Wegman Pia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004. Nückel H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics. 2004. Kaiser Rolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003. Tremblay Pierre-Benoit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003. Liu Wanqing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. BioEssays : news and reviews in molecular, cellular and developmental biology. 1998. Cole S P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of cancer therapy: getting personal. American journal of human genetics. 1998. Krynetski E Y, et al. PubMed

LinkOuts

Clinical Trials

These are trials that mention antineoplastic agents and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.